Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Oral paclitaxel yields better outcomes than IV paclitaxel in metastatic breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.20
Views: 711

Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras

Dr Gerardo Umanzor speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about his trial involving oral paclitaxel with encequidar for metastatic breast cancer.

After outlining the study methods and results, Dr Umanzor outlines the benefits and limitations of this work, as well as his future plans for the study.

Watch his press conference here

Read more about the study here

Related videos

follow us

SIOG metastatic renal cell carcinoma

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation